Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/11/2011

was $2.3 million, which includes $1.3 million of the $15 million paid to the Company's partner Auxilium Pharmaceuticals, Inc by Pfizer Inc. for the completion of the Marketing Authorization Application for XIAFLEX for Dupuytren's contracture in Europe.  The Company also received a milestone of $1.0 million related to the FDA's approval of XIAFLEX for Dupuytren's contracture in February 2010 and in connection with the notification in June 2010 to Auxilium of the Company's election not to commercially manufacture XIAFLEX.

Research and development expenses for the fourth quarter of 2010 were a credit of $34,256 compared to $0.1 million for the same period in 2009. This credit in research and development was mainly due to an adjustment during the quarter to the amount of third party lyophilization expenses reported to us by Auxilium. For the year ended December 31, 2010, research and development expenses were $1.2 million, compared to $0.5 million in 2009. This increase in research and development expenses was primarily due to third party development costs that are reimbursable to BioSpecifics.

General and administrative expenses for the fourth quarter of 2010 were $1.5 million, compared to $1.3 million for the same period in 2009. For the year ended December 31, 2010, general and administrative expenses were $6.5 million, compared to $4.8 million in 2009. The increase in general and administrative expenses was due to legal fees, stock based compensation and services related to investor relations partially offset by lower patent costs.

As of December 31, 2010, the Company had cash, cash equivalents and investments of $7.8 million, compared to $8.5 million on December 31, 2009.

Upcoming Milestones:

  • Auxilium anticipates reporting top-line results in the first half of 2012 for the Phase III double-blind studies of XIAFLEX for Peyronie's disease.

  • Auxilium plans to prioritize new pipeline indication(s) for XIAFL
    '/>"/>

  • SOURCE BioSpecifics Technologies Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
    2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
    3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
    4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
    5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
    6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
    7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
    8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
    9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
    10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
    11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
    (Date:4/30/2015)... (PRWEB) April 30, 2015 Biodata, ... notebook with integrated protocols and specimen management systems, ... solutions and consulting services for life science research, ... of Labguru’s newest feature: chemical structure and reaction ... features for biologists, bio-chemists, and more, the integration ...
    (Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
    (Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
    Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3
    ... accuracy: DNA vaccines that home in on DCs are ... develop new vaccines against infectious diseases is DNA vaccination. ... vaccine, the body converts the information in the DNA ... However, current DNA vaccines induce relatively weak immune responses ...
    ... UK, 6 March 2008 Elsevier, the world-leading ... and services, announced today Hybrid Materials 2009: The ... which will take place in Tours, France, 15-19 ... has experienced a 14% annual growth in published ...
    ... DNDN ) will release its fourth quarter financial results on,Thursday, March ... PT; 11:00 a.m. ET to review fiscal year 2007 financial results,and ... follows:, Time: 11:00 AM ... March 13, 2008 Dial-in: 1-877-548-7901 (domestic) or +1-719-325-4844 ...
    Cached Biology Technology:JCI online early table of contents: March 6, 2008 2JCI online early table of contents: March 6, 2008 3JCI online early table of contents: March 6, 2008 4Hybrid materials: Exciting interdisciplinary field offering future solutions for industry 2-Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET- 2
    (Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
    (Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
    (Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
    Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
    ... Des Moines, Iowa, USA March 18, 2008 A ... of Rwandan rain forest will have a greater range ... of Africas most ambitious forest restoration and ecological research efforts ... Park, said today that a 30-mile (50km) tree corridor will ...
    ... the United Kingdom and France have identified four ... of Creutzfeldt-Jakob disease. The study, published March 14th ... these subgroups could represent distinct prion strains in ... Prion diseases are transmissible neurodegenerative disorders characterized ...
    ... Take a deers body, attach a camels head and add ... odd-ball antelope with the enormous schnoz that lives on the isolated ... they are strange-looking due to over-hunting. Now, according to a ... as well. ...
    Cached Biology News:Rwanda conservation effort to link isolated chimps to distant forest 2Rwanda conservation effort to link isolated chimps to distant forest 3Asia's odd-ball antelope faces migration crisis 2
    ... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
    ... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
    AC input: 50-60 Hz230 V...
    ... Convenient, easy-to-use kits for arraying ... detection using common lab equipment. DiscoverLight ... analysis of your protein, cell lysate ... format. The kits include specially designed ...
    Biology Products: